May 10, 2021 5:46am BioNTech and Fosun Pharma expect to manufacture up to 1 billion doses of COVID-19 mRNA vaccine Comirnaty through a new joint venture in China. (Pixabay) As BioNTech makes inroads with its COVID-19 vaccine in Western countries under a partnership with Pfizer, the German biotech is bringing its work in China to the next level as the shot nears a local approval. BioNTech and Fosun Pharma are setting up a 50-50 joint venture to make and sell the COVID mRNA shot in China, with manufacturing capacity to produce up to 1 billion doses a year, Fosun said in a filing (PDF) to the Hong Kong Exchange on Sunday.